These results indicate that the inhibition of iNOS expression in melanoma cells by combinational use of melatonin and vemurafenib might be mediated by inhibiting the translocation of NF-κB p50/p65 from cytoplasm to cell nuclei and further inhibiting their binding at iNOS promoter. This evidence concerns the gene NFKB1 and melanoma.